• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia.

作者信息

Blouet Anaïse, Rousselet Marie-Christine, Le Bris Yannick, Ribourtout Bénédicte, Bouvier Anne, Cottin Laurane, Jouanneau-Courville Rébecca, Blanchet Odile, Ugo Valérie, Luque Paz Damien

机构信息

CH Cholet, service d'Oncologie Médicale, Cholet, France.

CHU Angers, Département d'Anatomo-Pathologie, Angers, France.

出版信息

Hemasphere. 2018 Feb 5;2(1):e29. doi: 10.1097/HS9.0000000000000029. eCollection 2018 Jan-Feb.

DOI:10.1097/HS9.0000000000000029
PMID:31723757
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6745955/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b12/6745955/9c08e46194b4/hs9-2-e29-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b12/6745955/ffb542b3068f/hs9-2-e29-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b12/6745955/9c08e46194b4/hs9-2-e29-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b12/6745955/ffb542b3068f/hs9-2-e29-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b12/6745955/9c08e46194b4/hs9-2-e29-g002.jpg

相似文献

1
Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia.伊马替尼治疗慢性髓性白血病揭示了一种先前存在的CALR突变型原发性血小板增多症。
Hemasphere. 2018 Feb 5;2(1):e29. doi: 10.1097/HS9.0000000000000029. eCollection 2018 Jan-Feb.
2
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.处于持久无治疗缓解期的Ph阳性慢性髓性白血病患者中的CALR阳性骨髓增殖性疾病：一例报告
Stem Cell Investig. 2017 Jun 23;4:57. doi: 10.21037/sci.2017.06.02. eCollection 2017.
3
Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia.CALR 突变的原发性血小板增多症中出现的急性淋巴细胞白血病。
Case Rep Hematol. 2016;2016:6545861. doi: 10.1155/2016/6545861. Epub 2016 Jan 21.
4
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
5
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.CALR 突变的低风险原发性血小板增多症患者抗血小板治疗与观察对比
Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12.
6
CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.CAL2免疫组织化学染色可准确识别骨髓增殖性肿瘤中的CALR突变。
Am J Clin Pathol. 2016 Oct;146(4):431-8. doi: 10.1093/ajcp/aqw135.
7
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.1 型与 2 型钙网织蛋白突变在原发性血小板增多症中的比较：一项 1027 例患者的协作研究。
Am J Hematol. 2014 Aug;89(8):E121-4. doi: 10.1002/ajh.23743. Epub 2014 May 16.
8
Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.利用片段分析和下一代测序技术检测克隆性和非克隆性血液系统疾病中的CALR突变
Am J Clin Pathol. 2016 Oct;146(4):448-55. doi: 10.1093/ajcp/aqw129.
9
Calreticulin in Essential Thrombocythemia: StressINg OUT the Megakaryocyte Nucleus.原发性血小板增多症中的钙网蛋白：使巨核细胞核应激
Front Oncol. 2017 May 22;7:103. doi: 10.3389/fonc.2017.00103. eCollection 2017.
10
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.原发性血小板增多症中的突变与血栓形成：与年龄和血栓形成史的预后相互作用。
Eur J Haematol. 2015 Jan;94(1):31-6. doi: 10.1111/ejh.12389. Epub 2014 Dec 4.

引用本文的文献

1
Chronic myeloproliferative neoplasms with concomitant mutation and translocation: diagnostic and therapeutic implications of a rare hybrid disease.伴有突变和易位的慢性骨髓增殖性肿瘤：一种罕见混合疾病的诊断和治疗意义
Front Cell Dev Biol. 2024 Mar 26;12:1391078. doi: 10.3389/fcell.2024.1391078. eCollection 2024.
2
Concurrent chronic myeloid leukemia and -mutated myeloproliferative neoplasm.同时存在的慢性髓性白血病和JAK2突变的骨髓增殖性肿瘤
EXCLI J. 2020 Jan 8;19:86-88. doi: 10.17179/excli2019-2063. eCollection 2020.
3
Philadelphia+ Chronic Myeloid Leukemia with CALR Mutation: A Case Report and Literature Review.

本文引用的文献

1
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.处于持久无治疗缓解期的Ph阳性慢性髓性白血病患者中的CALR阳性骨髓增殖性疾病：一例报告
Stem Cell Investig. 2017 Jun 23;4:57. doi: 10.21037/sci.2017.06.02. eCollection 2017.
2
CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene.伴有CALR突变和BCR-ABL1融合基因的CALR突变型原发性骨髓纤维化演变为慢性髓性白血病
Ann Hematol. 2016 Dec;95(12):2101-2104. doi: 10.1007/s00277-016-2827-3. Epub 2016 Oct 3.
3
Coexistence of p190 BCR/ABL Transcript and CALR 52-bp Deletion in Chronic Myeloid Leukemia Blast Crisis: A Case Report.
费城染色体阳性慢性髓性白血病伴 CALR 突变：病例报告及文献复习。
Cancer Res Treat. 2020 Jul;52(3):987-991. doi: 10.4143/crt.2019.703. Epub 2020 Jan 15.
慢性髓性白血病急变期p190 BCR/ABL转录本与CALR 52-bp缺失共存：一例报告
Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016002. doi: 10.4084/MJHID.2016.002. eCollection 2016.
4
JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens.JAK2V617F和CALR双突变在JAK2V617F等位基因负担较低的患者中更常见。
Leuk Lymphoma. 2016 Aug;57(8):1949-51. doi: 10.3109/10428194.2015.1116122. Epub 2016 Jan 4.
5
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.对伴有CALR突变和BCR-ABL1的罕见骨髓增殖性肿瘤患者酪氨酸激酶抑制剂治疗反应的见解
Blood. 2015 May 21;125(21):3360-3. doi: 10.1182/blood-2015-03-632893.
6
CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation.伴有CALR突变和BCR-ABL易位的CALR突变型原发性血小板增多症演变为慢性髓性白血病。
Blood. 2015 Apr 2;125(14):2309-11. doi: 10.1182/blood-2014-12-616847.
7
A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.非典型骨髓增殖性肿瘤中，BCR-ABL1之前出现的CALR突变。
N Engl J Med. 2015 Feb 12;372(7):688-90. doi: 10.1056/NEJMc1413718.
8
BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.在真性红细胞增多症患者发展为慢性髓性白血病的过程中，BCR-ABL1是JAK2V617F之后的继发事件。
Blood. 2013 Feb 14;121(7):1238-9. doi: 10.1182/blood-2012-11-467787.
9
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.原发性血小板增多症和真性红细胞增多症的反应标准：欧洲白血病网共识会议的结果
Blood. 2009 May 14;113(20):4829-33. doi: 10.1182/blood-2008-09-176818. Epub 2009 Mar 10.
10
Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.伴有BCR-ABL融合及JAK2V617F突变的慢性骨髓增殖性疾病
Leukemia. 2008 May;22(5):1059-62. doi: 10.1038/sj.leu.2404993. Epub 2007 Nov 1.